Generare
France
- Paris, Île-de-France
- 08/10/2024
- Seed
- $5,495,250
Natural products have contributed more than 500 molecules to pharmaceuticals.
However, conventional methods for discovering new natural products are increasingly ineffective.
Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution.
This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation.
- Industry Biotechnology Research
- Website https://generare.bio/
- LinkedIn https://www.linkedin.com/company/generare-bioscience/
Related People
Guillaume VandeneschFounder
France -
Paris, Île-de-France
Biotech Engineer with 10+ years exp in innovation & and consulting.
- Successful exit Possible Future 2022 to Capgemini Invent
Launched Generare in March 23' to revolutionize early drug discovery
Generare is a data-driven discovery platform that will revive the field of natural products, bringing this historically successful modality into the clinical pipelines.
Our POC in Nat Coms by Dr. Vincent Libis : http://bit.ly/3RL6JPL
Underlying tech awarded with ERC Starting Grant
More info about Generare available at https://docsend.com/view/dvwzjcj6n4vx36y9
AfterQuery | $30,000,000 | (Apr 10, 2026)
Plume (YC S24) | $3,900,000 | (Apr 10, 2026)
Rork | $15,000,000 | (Apr 10, 2026)
Haast | $12,000,000 | (Apr 10, 2026)
CareGlance Srl | $4,092,182 | (Apr 10, 2026)
Elorian AI | $55,000,000 | (Apr 10, 2026)
TeiaCare & Ancelia: AI for Care Homes | $8,184,645 | (Apr 10, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)
Felix(1) | $1,700,000 | (Apr 10, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
Golden Analytics | $7,000,000 | (Apr 9, 2026)